Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.34 |
| ▸ | AOC2 | O75106 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NQO1 | P15559 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1866194 | 0.88 | KDM4E (0.49) | KDM4ERECQLAPP | |
| SCHEMBL3167260 | 0.88 | KDM4E (0.49) | KDM4ERECQLAPP | |
| SCHEMBL28556579 | 0.88 | KDM4E (0.49) | KDM4ERECQLAPP | |
| SCHEMBL483029 | 0.85 | KDM4E (0.41) | KDM4ERECQLALDH1A1 | |
| SCHEMBL757706 | 0.83 | MMP2 (0.35) | NQO1 | |
| SCHEMBL17707239 | 0.82 | LTA4H (0.37) | NQO1 | |
| SCHEMBL3163804 | 0.80 | CTNNB1 (0.35) | CTNNB1KDM4ERECQLF2ELANE | |
| SCHEMBL919416 | 0.79 | KCNA3 (0.44) | KDM4ERECQLALDH1A1 | |
| SCHEMBL919131 | 0.79 | KCNA3 (0.39) | KDM4ERECQLALDH1A1 | |
| SCHEMBL9369921 | 0.79 | KCNA3 (0.50) | RECQLALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0292808-B1 | Substituted vinyl cephalosporins, process for their preparation and their use as medicines | BAYER AG (DE) | 1994-03-02 | — | — | EP | claimed |
| US-4988685-A | Cephalosporins derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | claimed |
| US-4849531-A | Process for the preparation of 2,3-epoxyamides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | claimed |
| EP-0292808-A2 | Substituted vinyl cephalosporins, process for their preparation and their use as medicines | BAYER AG (DE) | 1988-11-30 | — | — | EP | claimed |
| EP-0244717-A2 | Process for the preparation of 2,3-epoxyamides | BAYER AG (DE) | 1987-11-11 | — | — | EP | claimed |
| CN-115181082-B | Synthetic method of natural molecule Moracin M | 江苏集萃分子工程研究院有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-115181082-A | Synthetic method of natural molecule Moracin M | 江苏集萃分子工程研究院有限公司 | 2022-10-14 | — | — | CN | disclosed |
| EP-1630165-B1 | [1,2,4]TRIAZOLO[1,5-a]PYRIMIDIN-2-YLUREA DERIVATIVE AND USE THEREOF | NIPPON KAYAKU KK (JP) | 2010-03-31 | — | — | EP | disclosed |
| US-7598244-B2 | [1,2,4]triazolo[1,5,a]pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-10-06 | — | — | US | disclosed |
| US-7371773-B2 | Breast cancer resistance protein (BCRP) inhibitor | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 2008-05-13 | — | — | US | disclosed |
| US-7338941-B2 | Pharmaceutical compositions for lowering blood glucose and blood cholesterol levels | DIAKRON PHARMACEUTICALS, INC. (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2007-01-11 | — | — | US | disclosed |
| US-5171854-A | Antibiotics | BAYER AKTIENGESELLSCHAFT (DE) | 1992-12-15 | — | — | US | disclosed |
| EP-0429999-A1 | Novel cephalosporins, process for their preparation and their use as medicaments | BAYER AG (DE) | 1991-06-05 | — | — | EP | disclosed |
| US-4988685-A | Cephalosporins derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1991-01-29 | — | — | US | disclosed |
| US-4849531-A | Process for the preparation of 2,3-epoxyamides | BAYER AKTIENGESELLSCHAFT (DE) | 1989-07-18 | — | — | US | disclosed |
| CN-88103202-A | Vinyl cephalosporin compound that replaces and preparation method thereof and as the application of medicine | — | 1988-12-21 | — | — | CN | disclosed |
| EP-0292808-A2 | Substituted vinyl cephalosporins, process for their preparation and their use as medicines | BAYER AG (DE) | 1988-11-30 | — | — | EP | disclosed |
| EP-0284954-A2 | Cephalosporinderivatives, process for their preparation and their use in pharmaceutical products | BAYER AG (DE) | 1988-10-05 | — | — | EP | disclosed |
| EP-0244717-A2 | Process for the preparation of 2,3-epoxyamides | BAYER AG (DE) | 1987-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070010515-A1 | [1,2,4] Triazolo [1,5, a] pyrimidin-2-ylurea derivative and use thereof | HLA-C, TPMT, TAP1 | CTNNB1 3503/4885KDM4E 2344/4885RECQL 4010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.